Walleye Capital LLC Amgen Inc Put Options Transaction History

Walleye Capital LLC

$46.2 Billion
Q3 2024

Put Options

14 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$309.38 - $337.38 $19 Million - $20.7 Million	-61,300 Reduced 79.71%	15,600 $5.03 Million
Q2 2024 Aug 14, 2024	BUY	$262.75 - $319.31 $157,650 - $191,586	600 Added 0.79%	76,900 $24 Million
Q1 2024 May 15, 2024	SELL	$268.87 - $324.56 $3.23 Million - $3.89 Million	-12,000 Reduced 13.59%	76,300 $21.7 Million
Q4 2023 Feb 14, 2024	BUY	$255.7 - $288.46 $9.74 Million - $11 Million	38,100 Added 75.9%	88,300 $25.4 Million
Q3 2023 Nov 14, 2023	BUY	$218.65 - $271.46 $6.41 Million - $7.95 Million	29,300 Added 140.19%	50,200 $13.5 Million
Q2 2023 Aug 14, 2023	BUY	$214.27 - $253.37 $3.39 Million - $4 Million	15,800 Added 309.8%	20,900 $4.64 Million
Q1 2023 May 15, 2023	SELL	$225.79 - $275.2 $1.33 Million - $1.62 Million	-5,900 Reduced 53.64%	5,100 $1.23 Million
Q4 2022 Feb 14, 2023	SELL	$229.03 - $291.01 $709,993 - $902,131	-3,100 Reduced 21.99%	11,000 $2.89 Million
Q3 2022 Nov 14, 2022	BUY	$224.46 - $253.15 $3.16 Million - $3.57 Million	14,100 New	14,100 $3.18 Million
Q4 2019 Feb 14, 2020	SELL	$189.21 - $243.2 $1.46 Million - $1.87 Million	-7,700 Reduced 50.66%	7,500 $1.81 Million
Q3 2019 Nov 14, 2019	BUY	$174.11 - $208.62 $2.49 Million - $2.98 Million	14,300 Added 1588.89%	15,200 $2.94 Million
Q2 2019 Aug 14, 2019	SELL	$166.7 - $195.41 $83,350 - $97,705	-500 Reduced 35.71%	900 $166,000
Q1 2019 May 15, 2019	SELL	$180.87 - $203.88 $2.3 Million - $2.59 Million	-12,700 Reduced 90.07%	1,400 $266,000
Q3 2018 Nov 14, 2018	BUY	$185.29 - $208.89 $2.61 Million - $2.95 Million	14,100 New	14,100 $2.92 Million

Others Institutions Holding AMGN

# of Institutions

3,119

Shares Held

410M

Call Options Held

7.56M

Put Options Held

7.2M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $152B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Capital LLC with notifications on news.

Account